CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00026949
NCT00026949N/ACompleted

Pharmacokinetics of Etoposide in Patients With Breast Cancer Receiving High-Dose Etoposide

National Cancer Institute (NCI)·observational·Posted Nov 15, 2001·Updated Mar 4, 2008

In Brief

An observational study for Breast Cancer. Completed, across 1 site.

Detailed Summary

This study will examine how the body handles etoposide, a drug used to treat breast cancer. The knowledge gained may lead to more effective use of the drug with fewer side effects in the future. Breast cancer patients who are receiving etoposide as part of their treatment may participate in this study. Patients will have 18 blood samples (about a teaspoon or less each) drawn over a 72-hour period during and after their infusion of etoposide. The initial blood samples cannot be taken from the same intravenous line (small tube placed in a vein) used to deliver the etoposide, so a second line may have to be placed temporarily to obtain these samples.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 15, 2001
Enrollment StartAug 1, 1999
Study CompletionAug 1, 2004
TodayJul 2, 2026
Posted 24.6 years ago